Article info

Download PDFPDF
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy

Authors

  1. Correspondence to Dr Sinchita Roy-Chowdhuri, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA; sroy2{at}mdanderson.org
View Full Text

Citation

Faber E, Grosu H, Sabir S, et al
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy

Publication history

  • Received April 1, 2021
  • Revised April 12, 2021
  • Accepted April 13, 2021
  • First published May 5, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.